Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

ESMO Open - Tập 7 - Trang 100333 - 2022
J. Wolf1, Å. Helland2, I.-J. Oh3, M.R. Migliorino4, R. Dziadziuszko5, A. Wrona5, J. de Castro6, J. Mazieres7, F. Griesinger8, M. Chlistalla9, A. Cardona9, T. Ruf9, K. Trunzer9, V. Smoljanovic9, S. Novello10
1Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
2Department of Cancer Genetics and Department of Oncology, Institute for Cancer Research, Oslo University Hospital, University of Oslo, Oslo, Norway
3Department of Internal Medicine, Chonnam National University Medical School, Hwasun-gun Jeollanam-do, Republic of Korea
4Pulmonary Oncology Unit, Azienda Ospedaliera San Camillo Forlanini Hospital, Rome, Italy
5Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
6Department of Medical Oncology, La Paz University Hospital, IdiPAZ, Madrid, Spain
7Department of Pneumology, Toulouse University Hospital, Paul Sabatier University, Toulouse, France
8Department of Hematology and Oncology, Pius Hospital, University Medicine Oldenburg, Oldenburg, Germany
9F. Hoffmann-La Roche Ltd, Basel, Switzerland
10Department of Oncology, University of Turin, Orbassano, Italy

Tài liệu tham khảo

Barlesi, 2016, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, 387, 1415, 10.1016/S0140-6736(16)00004-0

Tian, 2017, Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients, Lung Cancer, 114, 90, 10.1016/j.lungcan.2017.11.001

Hanna, 2021, Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) Joint Guideline Update, J Clin Oncol, 39, 1040, 10.1200/JCO.20.03570

Planchard, 2018, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Updated September 2020, Ann Oncol, 29, iv192, 10.1093/annonc/mdy275

Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, N Engl J Med, 377, 829, 10.1056/NEJMoa1704795

Mok, 2020, Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study, Ann Oncol, 31, 1056, 10.1016/j.annonc.2020.04.478

Ou, 2016, Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global study, J Clin Oncol, 34, 661, 10.1200/JCO.2015.63.9443

Shaw, 2016, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicenter, phase 2 trial, Lancet Oncol, 17, 234, 10.1016/S1470-2045(15)00488-X

Novello, 2018, Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study, Ann Oncol, 29, 1409, 10.1093/annonc/mdy121

Gainor, 2016, Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer, Cancer Discov, 6, 1118, 10.1158/2159-8290.CD-16-0596

Doebele, 2012, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer, Clin Cancer Res, 18, 1472, 10.1158/1078-0432.CCR-11-2906

Dagogo-Jack, 2016, Crizotinib resistance: implications for therapeutic strategies, Ann Oncol, 27, iii42, 10.1093/annonc/mdw305

Rothenstein, 2018, ALK inhibitors, resistance development, clinical trials, Curr Oncol, 25, S59, 10.3747/co.25.3760

Noe, 2020, ALK mutation status before and after alectinib treatment in locally advanced or metastatic ALK-positive NSCLC: pooled analysis of two prospective trials, J Thorac Oncol, 15, 601, 10.1016/j.jtho.2019.10.015

Qin, 2020, Prognostic value of TP53 concurrent mutations for EGFR-TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis, BMC Cancer, 20, 328, 10.1186/s12885-020-06805-5

Song, 2019, Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer, Cancer Med, 8, 1551, 10.1002/cam4.2043

Aisner, 2018, The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations – the Lung Cancer Mutation Consortium (LCMC2), Clin Cancer Res, 24, 1038, 10.1158/1078-0432.CCR-17-2289

Yang, 2017, Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer, J Thorac Oncol, 12, 1552, 10.1016/j.jtho.2017.06.070

Kodama, 2014, Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases, Cancer Chemother Pharmacol, 74, 1023, 10.1007/s00280-014-2578-6

Nakagawa, 2020, Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer, Lung Cancer, 139, 195, 10.1016/j.lungcan.2019.11.025

Zhou, 2019, Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study, Lancet Respir Med, 7, 437, 10.1016/S2213-2600(19)30053-0

Shaw, 2017, Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 18, 874, 10.1016/S1470-2045(17)30339-X

Huber, 2020, Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial, J Thorac Oncol, 15, 404, 10.1016/j.jtho.2019.11.004

Besse, 2018, Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): updated efficacy and safety, J Clin Oncol, 36, 9032, 10.1200/JCO.2018.36.15_suppl.9032

Malapelle, 2019, Personalized genomic medicine: non-small-cell lung cancer and anaplastic lymphoma kinase, J Transl Genet Genom, 3, 3

Christopoulos, 2019, Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma, Int J Cancer, 144, 190, 10.1002/ijc.31893

Kron, 2018, Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer, Ann Oncol, 29, 2068, 10.1093/annonc/mdy333

Thông tin
Thông tin xuất bản

ESMO Open

Tập 7

100333

Thông tin tác giả